Phase 2 N=52 Efficacy and Safety of Sunitinib in Metastatic Gastric Cancer
Gastric Adenocarcinoma · Barrett Esophagus
Primary: Objective Response Rate (ORR) — 3.92 Participants (%)
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=200 Interferon Alpha Lozenges in the Prevention of Winter Colds and Flu
Upper Respiratory Tract Infections
Primary: Frequency of Influenza-like Illness — 54; 62; 16; 28 participants — p=0.25
Phase 2 N=60 Alemtuzumab/Fludarabine for Relapsed/Refractory B-cell Chronic Lymphocytic Leukemia (B-CLL)
Leukemia, Lymphocytic, Chronic, B-Cell
Primary: Complete Response (CR) — 8.3 Percentage of participants with CR — p=0.014
Phase 2 N=59 Treatment of Oral Warts in HIV+ Patients
Papillomatosis · HIV Infections
Primary: Change in Total Oral Mucosal Area Covered by Warts. — 11; 2 participants — p=0.30
Phase 2 N=52 Pharmacogenomic & Phase II Study of Gemcitabine and Pemetrexed in Non-Small-Cell Lung Cancer.
Lung Cancer
Primary: Disease Response - Radiographic — 1; 16 participants
Phase 2 N=41 A Phase II Study of AZD4877 (a Novel Anti-mitotic Agent) in Advanced Bladder Cancer
Bladder Cancer · Transitional Cell Bladder Cancer · Urethra Cancer
Primary: Objective Response Rate (ORR) as Evaluated by Response Evaluation Criteria In Solid Tumors (RECIST) — 2.6 Percengate of participants
Phase 2 N=276 A Dose-ranging Safety and Efficacy Study of Ecallantide to Reduce Surgical Blood Loss Volume
Bloodloss · Surgical Procedures, Operative
Primary: Cumulative Volume of Packed Red Blood Cells Transfused at 12 Hours Post Surgery — 401.9; 383.1; 410.3; 377.6 mL — p=0.474
Phase 2 N=180 Study Evaluating A 13-Valent Pneumococcal Conjugate Vaccine Administered To Infants In Korea
Pneumococcal Vaccine
Primary: Percentage of Participants Achieving a Serotype-specific Immunoglobulin G (IgG) Antibody Level Greater Than or Equal to (≥) 0.35 Micrograms Per Milliliter (Mcg/mL)…
Phase 2 N=19 Study Evaluating Biomarkers In Relapsed/Refractory Pediatric Solid Tumors
Adenocarcinoma · Neoplasms
Primary: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs): Part 1 — 4; 5; 3; 7 participants
Phase 2 N=59 Chemoimmunotherapy Study for Patients With Epithelial Ovarian Cancer
Ovarian Cancer · Fallopian Tube Cancer · Peritoneal Cancer
Primary: Number of Patients With Response — 9; 21; 24 Participants
Phase 2 N=111 Study of AMG 162 in Subjects With Advanced Cancer Currently Being Treated With Intravenous (IV) Bisphosphonates
Bone Metastases in Men With Hormone-Refractory Prostate Cancer · Bone Metastases in Subjects With Advanced Breast Cancer · Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma
Primary: uNTx (Corrected by Creatinine) < 50 Nmol/mmol at Week 13 — 10; 21; 28 Participants — p=<0.001
Phase 2 N=21 A Study of the Pharmacokinetics of Testosterone Metered Dose (MD)-Lotion Formulations
Hypogonadism
Primary: Pharmacokinetics of Total Testosterone, Dihydrotestosterone, Free Testosterone: Time of Maximal Concentration (Tmax) — 8.00; 12.00; 4.25; 15.98 hours (h)
Phase 2 N=255 Denosumab (AMG 162) in Bisphosphonate Naive Metastatic Breast Cancer
Breast Cancer · Metastases · Bone Metastases in Subjects With Advanced Breast Cancer
Primary: Percent Change From Baseline to Week 13 in Creatinine-adjusted Urinary N-telopeptide (uNTx/Cr) — -10.19; -52.87; -54.21; -57.36 Percent change — p=0.245
Phase 2 N=65 Extension Study of Proellex in Women Who Have Previously Completed Study ZPU 003
Uterine Fibroids
Primary: The Change in Menorrhagia From the Baseline of ZPU-003 to the End of Each Off Drug Interval(ODI) Within the ZPU-003 Extension Study and the Baseline of ZPU-003 to the…
Phase 2 N=96 Open-Label, Phase 2, Proof of Concept Study in Multiple Myeloma - Denosumab
Relapsed or Plateau-Phase Multiple Myeloma
Primary: Complete Response or Partial Response Based on M-Protein Assessments Only — 0; 0 Participants